Choose IXINITY®
Offer your patients predictable bleed control and an established safety profile

*The pharmacokinetics of IXINITY have been evaluated in 32 previously treated patients (PTPs) ≥12 years of age with severe to moderately severe hemophilia B.1
Watch as real patients share their IXINITY IXperience™
Watch as real patients share their IXINITY IXperience™
Success stories >

Find out if IXINITY is right for your patients
Patient profiles >
References: 1. IXINITY [coagulation factor IX (recombinant)]. Prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022. 2. Data on file. Chicago, IL, Medexus Pharma, Inc.